Literature DB >> 28481998

Minimally invasive heart valve surgery: influence on coagulation and inflammatory response.

Domenico Paparella1,2, Crescenzia Rotunno1,2, Pietro Guida1, Mattia Travascia1, Micaela De Palo1, Andrea Paradiso1, Alessandro Carrozzo1, Ruggero Rociola1.   

Abstract

OBJECTIVES: Minimally invasive valve surgery (MIVS) is associated with improved clinical outcome but longer cardiopulmonary bypass (CPB) time. The aim of the present study is to compare inflammatory and coagulation parameters in patients undergoing minimally invasive or standard valve surgery.
METHODS: A prospective non-randomized study was performed enrolling 79 patients undergoing mitral (20 right mini-thoracotomy and 18 standard sternotomy) and aortic valve (20 mini-sternotomy and 21 standard sternotomy) procedures. Blood samples were collected perioperatively to measure prothrombin fragment 1.2 (PF1.2, thrombin generation), plasmin antiplasmin complex (PAP, fibrinolysis), interleukin-6 (IL-6, inflammation). Plasma free haemoglobin (f-Hb) was assessed to evaluate haemolysis.
RESULTS: Patients in the minimally invasive group were younger and had less comorbidities CPB and cross-clamp times were comparable considering both aortic and mitral procedures, but longer in the mini-thoracotomy group. IL-6 and PAP were reduced in the minimally invasive group, particularly 2 h after CPB (respectively 102 ± 114 vs 34 ± 49 pg/ml, P < 0.001 and 2137 ± 1046 vs 1207 ± 675 ng/ml, P < 0.001), PF1.2 was also reduced during and after the operation (688 ± 514 vs 571 ± 470, P = 0.02; 1600 ± 1185 vs 1042 ± 548, P < 0.001; 1487 ± 676 vs 1042 ± 541). Despite the use of vacuum-assisted active venous drainage (VAVD) f-Hb was significantly reduced in the minimally invasive group. The other routine biomarkers such as C-reactive protein, fibrinogen and cTnI were also reduced in the minimally invasive group.
CONCLUSIONS: In a selected cohort of patients MIVS is associated to reduced inflammatory reaction and coagulopathy, supporting the clinical evidence of reduced postoperative bleeding and lower transfusion rate. Our data offer further suggestion supporting the adoption of minimally invasive approaches.
© The Author 2017. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Adult cardiac; Aortic valve; Minimally invasive mitral surgery; Mitral valve

Mesh:

Year:  2017        PMID: 28481998     DOI: 10.1093/icvts/ivx090

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  5 in total

1.  Sutureless aortic valve replacement in high risk patients neutralizes expected worse hospital outcome: A clinical and economic analysis.

Authors:  Emmanuel Villa; Margherita Dalla Tomba; Antonio Messina; Andrea Trenta; Federico Brunelli; Marco Cirillo; Zean Mhagna; Giovanni Alfonso Chiariello; Giovanni Troise
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

2.  Dermabond as a Novel Solution for Needle-Hole Repair in Arterial Cannula while on Extracorporeal Membrane Oxygenation Therapy.

Authors:  Janani S Reisenauer; James R Neal; David L Joyce
Journal:  J Extra Corpor Technol       Date:  2019-09

3.  Minimally invasive surgical versus transcatheter aortic valve replacement: A multicenter study.

Authors:  Domenico Paparella; Giuseppe Santarpino; Pietro Giorgio Malvindi; Marco Moscarelli; Alfredo Marchese; Pietro Guida; Carmine Carbone; Renato Gregorini; Luigi Martinelli; Chiara Comoglio; Roberto Coppola; Alberto Albertini; Alberto Cremonesi; Armando Liso; Khalil Fattouch; Maria Avolio; Natale D Brunetti; Giuseppe Speziale
Journal:  Int J Cardiol Heart Vasc       Date:  2019-04-28

Review 4.  Thrombogenic and Inflammatory Reactions to Biomaterials in Medical Devices.

Authors:  Carlos A Labarrere; Ali E Dabiri; Ghassan S Kassab
Journal:  Front Bioeng Biotechnol       Date:  2020-03-12

5.  Minimally invasive implantation and decreased inflammation reduce osteoinduction of biomaterial.

Authors:  Zifan Zhao; Qin Zhao; Bin Gu; Chengcheng Yin; Kailun Shen; Hua Tang; Haibin Xia; Xiaoxin Zhang; Yanbing Zhao; Xiangliang Yang; Yufeng Zhang
Journal:  Theranostics       Date:  2020-02-18       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.